Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Vaxcyte, Inc. Market Cap
From what 3 stock analysts predict, the share price for Vaxcyte, Inc. (PCVX) might decrease by 0.35% in the next year. This is based on a 12-month average estimation for PCVX. Price targets go from $69.00 to $80.00. The majority of stock analysts believe PCVX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Vaxcyte, Inc. has a total of 3 Wall St Analyst ratings. There are 3 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Vaxcyte, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| thomas shrader BTIG | Buy | $76.0 | maintained | Jan 29, 2024 |
| salim syed Mizuho Securities | Buy | $69.0 | maintained | Jan 29, 2024 |
| david risinger Leerink Partners | Buy | None | reiterated | Jan 5, 2024 |
| jason gerberry Bank of America Securities | Buy | $80.0 | maintained | Jan 4, 2024 |
| boris peaker TD Cowen | Buy | None | reiterated | Nov 6, 2023 |
| louise chen Cantor Fitzgerald | Buy | $70.0 | reiterated | Aug 8, 2023 |
| joseph stringer Needham | Buy | $58.0 | reiterated | May 9, 2023 |
| seamus fernandez Guggenheim | Buy | $65.0 | maintained | Feb 28, 2023 |
| roger song Jefferies | Buy | $56.0 | maintained | Nov 7, 2022 |
| kelechi chikere Jefferies | Buy | $50.0 | initiatedcoverage | Jun 24, 2021 |
| alan carr Needham | Hold | None | rated | Feb 1, 2021 |
| biren amin Jefferies | Buy | $41.0 | initiatedcoverage | Jul 7, 2020 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
When did it IPO
2020
Staff Count
158
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Grant E. Pickering M.B.A.
Market Cap
$8.12B
In 2023, PCVX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PCVX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
APPF-USD
$230.24
LNW-USD
$89.71
GNTX-USD
$35.26
PARA-USD
$12
JAZZ-USD
$126.36
MKTX-USD
$219.04
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
